We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Zions Bancorporation
ZION
$10.1B
| $11.9M | 0.16% |
266,475
-59,318
| -18% | -$2.56M |
|
152
Hartford Financial Services
HIG
$38.5B
| $11.6M | 0.15% |
192,002
-48,740
| -20% | -$2.85M |
|
153
Tesla
TSLA
$1.24T
| $11.6M | 0.15% |
721,500
+62,190
| +9% | +$974K |
|
154
Costco
COST
$415B
| $11.4M | 0.15% |
39,742
+2,733
| +7% | +$769K |
|
155
Morgan Stanley
MS
$337B
| $11.4M | 0.15% |
267,458
+120,645
| +82% | +$5.16M |
|
156
Pfizer
PFE
$140B
| $11.3M | 0.15% |
330,539
-35,532
| -10% | -$1.29M |
|
157
Pinduoduo
PDD
$118B
| $11.2M | 0.15% |
349,000
+73,000
| +26% | +$1.95M |
|
158
United Parcel Service
UPS
$97.6B
| $11.2M | 0.15% |
93,591
+219
| +0.2% | +$25K |
|
159
Colgate-Palmolive
CL
$72.6B
| $11.2M | 0.15% |
152,167
-15,214
| -9% | -$1.1M |
|
160
Chevron
CVX
$388B
| $11.1M | 0.15% |
93,597
-37,709
| -29% | -$4.58M |
|
161
Hilton Worldwide
HLT
$74B
| $11M | 0.15% |
117,926
+16,450
| +16% | +$1.56M |
|
|
HOLX
162
DELISTED
Hologic
HOLX
| $10.9M | 0.14% |
215,864
+59,295
| +38% | +$2.92M |
|
|
ZGNX
163
DELISTED
Zogenix, Inc.
ZGNX
| $10.8M | 0.14% |
270,700
+35,000
| +15% | +$1.61M |
|
164
Tenable Holdings
TENB
$3.56B
| $10.8M | 0.14% |
+481,879
| New | +$12.2M |
|
165
Delta Air Lines
DAL
$55.9B
| $10.8M | 0.14% |
187,115
-28,592
| -13% | -$1.69M |
|
166
Zimmer Biomet
ZBH
$17.7B
| $10.7M | 0.14% |
80,545
-86,663
| -52% | -$11.2M |
|
167
Capital One
COF
$124B
| $10.7M | 0.14% |
117,447
-15,557
| -12% | -$1.4M |
|
168
Cigna
CI
$76.6B
| $10.6M | 0.14% |
69,887
-2,185
| -3% | -$356K |
|
169
Consolidated Edison
ED
$41.6B
| $10.5M | 0.14% |
111,359
-33,019
| -23% | -$2.93M |
|
170
lululemon athletica
LULU
$13B
| $10.5M | 0.14% |
54,486
-4,484
| -8% | -$838K |
|
|
APLS
171
DELISTED
Apellis Pharmaceuticals
APLS
| $10.5M | 0.14% |
434,700
-93,000
| -18% | -$2.56M |
|
172
Caterpillar
CAT
$409B
| $10.5M | 0.14% |
82,836
-94,905
| -53% | -$12.1M |
|
|
DRNA
173
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $10.3M | 0.14% |
+719,500
| New | +$10.3M |
|
174
Karyopharm Therapeutics
KPTI
$168M
| $10.3M | 0.14% |
71,482
-58,303
| -45% | -$7.9M |
|
175
Lamb Weston
LW
$6.82B
| $10.3M | 0.14% |
141,671
-36,179
| -20% | -$2.48M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.